Manufacturer
AstraZeneca Pharmaceuticals LP
Contents
Dapagliflozin
Indication
Adjunct to diet & exercise to improve glycaemic control in adults ≥18 yr w/ type 2 DM as monotherapy; add-on combination w/ metformin, sulfonylurea; insulin, DPP4 inhibitor, in combination w/ metformin & a sulfonyurea & as initial combination therapy w/ metformin (includes poor prospects for response to metformin monotherapy).
Instruction
May be taken with or without food.
Drug interaction
Increased diuretic effects & risk of dehydration & hypotension w/ thiazide & loop diuretics. Hypoglycaemia w/ insulin & insulin secretagogues eg, sulphonylurea. Increased risk of bladder cancer in diabetic patient w/ pioglitazone.
Malaysia
